Ratutrelvir for COVID-19: real-time analysis

Download Image

Post

c19early.org

Ratutrelvir for COVID-19

1 study with 50 patients

Significantly lower risk for recovery.

COVID-19 Ratutrelvir studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)14%

RCTs (1)14%

Early (1)14%

00.511.5+

← Ratutrelvir
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Jan 13	Dokukina et al., NCT07157007	Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
Jan 13	14% improved recovery (p=0.01). Interim results showing improved time-to-sustained symptom alleviation and resolution with ratutrelvir.